SAN DIEGO, CA and PHOENIX, AZ--(Marketwire - August 19, 2008) - Medistem Laboratories (OTCBB: MEDS) today reported positive efficacy data supporting development of its lead product, the Endometrial Regenerative Cell (ERC) for treatment of an advanced form of peripheral artery disease known as critical limb ischemia.
